Theravance Biopharma, Inc. (NASDAQ:TBPH) Short Interest Down 14.5% in April

Theravance Biopharma, Inc. (NASDAQ:TBPH) was the recipient of a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 6,430,000 shares, a decrease of 14.5% from the March 31st total of 7,520,000 shares. Currently, 14.7% of the company’s shares are sold short. Based on an average daily volume of 367,200 shares, the days-to-cover ratio is presently 17.5 days.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on TBPH shares. Evercore ISI lowered shares of Theravance Biopharma from an “outperform” rating to an “inline” rating in a report on Monday, January 8th. BTIG Research began coverage on Theravance Biopharma in a research note on Friday, April 12th. They issued a “buy” rating and a $21.00 target price on the stock.

Theravance Biopharma Stock Performance

Shares of NASDAQ:TBPH opened at $8.44 on Wednesday. Theravance Biopharma has a 52-week low of $8.21 and a 52-week high of $11.98. The firm has a market capitalization of $409.85 million, a P/E ratio of -8.70 and a beta of 0.36. The stock has a 50 day moving average price of $9.07 and a 200-day moving average price of $9.67.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.02). The firm had revenue of $17.57 million for the quarter, compared to analysts’ expectations of $17.49 million. Theravance Biopharma had a negative net margin of 96.12% and a negative return on equity of 19.31%. On average, equities analysts forecast that Theravance Biopharma will post -0.84 EPS for the current fiscal year.

Hedge Funds Weigh In On Theravance Biopharma

Institutional investors and hedge funds have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. boosted its holdings in Theravance Biopharma by 324.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,759 shares of the biopharmaceutical company’s stock worth $65,000 after acquiring an additional 4,402 shares in the last quarter. Newtyn Management LLC grew its position in Theravance Biopharma by 12.3% during the 3rd quarter. Newtyn Management LLC now owns 1,841,560 shares of the biopharmaceutical company’s stock valued at $15,893,000 after purchasing an additional 201,104 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Theravance Biopharma by 4.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 44,532 shares of the biopharmaceutical company’s stock valued at $384,000 after purchasing an additional 1,993 shares in the last quarter. Bleakley Financial Group LLC purchased a new position in Theravance Biopharma in the fourth quarter worth about $141,000. Finally, GSA Capital Partners LLP raised its holdings in Theravance Biopharma by 1,536.4% in the third quarter. GSA Capital Partners LLP now owns 325,985 shares of the biopharmaceutical company’s stock worth $2,813,000 after buying an additional 306,064 shares during the last quarter. Institutional investors own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.